ArticleThe journal of prevention of Alzheimer's disease2019
Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
Article in The journal of prevention of Alzheimer's disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 118 citations in OpenAlex.
- Mediterranean Diet Modulation of Neuroinflammation-Related Genes in Elderly Adults at High Cardiovascular Risk.Nutrients · 2024Trial
- Assessment of Plasma Amyloid-β42/40 and Cognitive Decline Among Community-Dwelling Older Adults.JAMA network open · 2020Trial
- Combined Effects ofInternational journal of molecular sciences · 2026Article
- Plasma Concentrations of Amyloid-β Peptides, BACE-1, and Tau Proteins in Alzheimer's Disease.Turkish journal of pharmaceutical sciences · 2026Article
- BRICHOS-Biased Inhibition Contributes to Aβ42 Dominance in Parenchymal Plaques Despite Higher Aβ40 Abundance and Coaggregation Capability.Biomacromolecules · 2026Article
- Glymphatic dysfunction associates with regional white matter hyperintensities and plasma amyloid-β burden across the Alzheimer's disease continuum.Psychological medicine · 2026Article
- Evidence of APOE4-related brain vulnerabilities in verbal memory systems in midlife women.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Estimation of positron emission tomography amyloid load and related biomarkers in Alzheimer's disease using evoked potential tomography EEG: development and internal validation in a cross-sectional cohort.Alzheimer's research & therapy · 2026Article
- Correlation analysis of positive Alzheimer's disease plasma biological markers with plasma immune cell and clinical characteristics in mild cognitive impairment patients in China.BMC immunology · 2026Article
- Incidence of altered proteins in the aging brain: Implications for biological diagnostic markers.Journal of Alzheimer's disease : JAD · 2026Article
- Plasma ATN biomarkers across the alzheimer's disease continuum in a Chilean community- and clinic-based cohort.Alzheimer's research & therapy · 2026Article
- Reduced Plasma Aβ Peptides but Stable NfL and GFAP in Major Depressive Disorder.International journal of molecular sciences · 2026Article
- Preliminary Investigation of the Association Between Epigenetic Aging Acceleration and Amyloid Biomarkers in Bipolar Disorder.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2026Article
- Neuroinflammation and blood-brain barrier dysfunction in cerebral small vessel disease: mechanisms, biomarkers, and therapeutic implications.European journal of medical research · 2026Review
- Using Plasma Amyloid Beta Oligomer to Screen in Alzheimer's Disease: A Pilot Study.International journal of molecular sciences · 2026Article
- PET imaging utility of a novel Aβ-tracking PET radiotracer, [Journal of translational medicine · 2026Article
- Microfluidic nanomagnetically isolated neuron- and astrocyte-derived extracellular vesicles to differentiate Lewy body and Alzheimer's disease.Npj biosensing · 2026Article
- Association between Alzheimer's disease-related genes and neurodegenerative blood-based biomarkers in Indian adults.Frontiers in aging neuroscience · 2026Article
- Review
- Blood biomarkers and artificial intelligence: toward precision medicine in Alzheimer's disease.Frontiers in aging neuroscience · 2026Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEasily accessible biomarkers are needed for the early identification of individuals at risk of developing Alzheimer's disease (AD) in large population screening strategies.
objectivesThis study evaluated the potential of plasma β-amyloid (Aβ) biomarkers in identifying early stages of AD and predicting cognitive decline over the following two years.
designTotal plasma Aβ42/40 ratio (TP42/40) was determined in 83 cognitively normal individuals (CN) and 145 subjects with amnestic mild cognitive impairment (a-MCI) stratified by an FDG-PET AD-risk pattern.
resultsSignificant lower TP42/40 ratio was found in a-MCI patients compared to CN. Moreover, a-MCIs with a high-risk FDG-PET pattern for AD showed even lower plasma ratio levels. Low TP42/40 at baseline increased the risk of progression to dementia by 70%. Furthermore, TP42/40 was inversely associated with neocortical amyloid deposition (measured with PiB-PET) and was concordant with the AD biomarker profile in cerebrospinal fluid (CSF).
conclusionsTP42/40 demonstrated value in the identification of individuals suffering a-MCI, in the prediction of progression to dementia, and in the detection of underlying AD pathology revealed by FDG-PET, Amyloid-PET and CSF biomarkers, being, thus, consistently associated with all the well-established indicators of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.